munocomplexes to the Fc receptors on cells. Other mechanisms of action include interaction with complement and cytokines, anti-idiotypic property, decrease in the action of dendtritic cells and T and B cell activation and differentiation (2-5).
1) Fc receptor-mediated action
Fc receptors which are found in most of the hematopoetic cells (macrophages, dendritic cells, microglias and neutrophils) act as activators and inhibitors. The fatal effects of these cells are reduced by decreasing reseptor-mediated cytokine and other proinflammatory mediator release from the macrophages.
2) T cell mediated action
T cells play an important role on the adaptive immune system. Intravenous immunoglobulins cause to programmed T cell inactivation and/or death.
3) Action on B cells
Many autoimmune diseases occur because of autoantibodies released from B cells. Intravenous immunoglobulin acts on B cells with different ways. It causes to down-regulation of the antibodies formed by B cells. It neutralizes pathogenic antibodies, since it includes many anti-idiotypes (anti-FVIII, anti-DNA, anti-tyroglobulin, anti-neuroblastoma, anti-laminin). It inhibits B cell growth by blocking some receptors on B cells. It inhibits release of autoantibodies from B cells with its anti-CD5 content. It contributes to pathological autoantibody catabolism. It realizes this by FcRn receptor which plays in IgG catabolism. It neutralizes BAFF-B cell activating factor which provides B cell differentiation.
4) Action on dendritic cells
Dentritic cells are thought to be responsible of primary immune response, since they are involved in immature T cell activation. High dose IVIG which is given to lupus patients inhibits expression of CD80/86 and Human Leukocyte Antigen (HLA) (efficient in antigen presentation and T cell activation) by inhibiting dendritic cell differentiation.
5) Action on cytokine production
Interferon (IFN)-gamma, interleukin (IL)-4 and IL-5 which are proinflammatory/antiinflammatory cytokines are released from activated Th1 and Th2 cells. The balance between these cells are disturbed in autoimmune diseases and Th1 derived cytokines become predominant. Since intravenous immunoglobulins include antibodies against Th1 cytokines, they help in elimination of this imbalance.
6) Action on the complement system
They inhibit activation by binding to C3b and C4b in the complement system.
7) Intravenous immunoglobulins inhibit B cell
functions by behaving like antiidiotypic antibodies An ideal IVIG preperation: The number of donors should be more than 4000 (5000-10000), the half-life should be longer than 20 days, the monomeric IgG should be higher than 90%, IgG subgroup distribution should be appropriate and Fc functions should be complete (complement binding and opsonization), it should not include pyrogenic substances, agregates or vasoactive substances, it should have few side effects, it should include minimal IgA, it should be sterile, regular and stable and should be easly soluble if it is powder and it should be inexpensive (6). In Table 1 , the properties of some IVIG preperations found in Turkey are shown.
Side effects
Side effects against intravenous immunoglobulin products have been reported with a rate of 20% (7) . Although most of these side effects are minor and transient, severe side effects are observed with a rate of 2-6% (8). The side effects can be examined under the titles of immediate, delayed and late side effects (9). 1) Immediate side effects: They occur in 6 hours after the beginning of infusion.
-Pain, swelling, erythema at the site of infusion -Head pain, nausea, vomiting -Myalgia, back pain, arhtralgia -Fever, sweating, erythema in the face, hypo/hypertension, tachycardia -Anaphylactic/anaphylactoid reaction -Anxiety, fatigue -Anaphylaxis in patients with IgA deficieny: Although it is thought to be related with anti-IgA antibodies found in the structure of IgG and IgE, it is still controversial. Therefore, IgA preperations with lower IgA content should be preferred in these patients (10) . Subcutaneous IVIG can be used, if allergic reaction develops despite use of preperations with low IgA content (11).
2) Delayed side effects: these side effects develop in 6 hours-1 week. a) Neurological side effects: Neurological side effects include migraine like headache and aseptic meningitis. Nausea, vomiting, photophobia and muscle cramps may accompany headache. Some headache types are resistant and very severe and nuchal rigidity and fever may also accompany pain. In this situation, pleocytosis is observed in cerebrospinal fluid when lumbar puncture is performed and the picture is called aseptic meningitis. Aseptic meningitis has been mostly related with high dose IVIG useage (9).
b) Thromboembolic complications:
Coronary artery disease, cerebrovascular disease, previous embolic attack, smoking, hypertension, diabetes, hyperlipidemia are risk factors for thromboembolism. In addition, hereditary thrombophilia, catheter, autoimmunity, estrogen use in advanced age and immobilization are also among the risk factors. These complications are generally observed after administration of a high dose and rapid infusion. Thromboembolis events raging from regional thromboembolic event to acute myocardial infarction, coronary syndrome, stroke and deep vein thrombosis (9, 12, 13) .
c) Nephrological side effects: Acute renal failure, hyponatremia and pseudohyponatremia are the main nephrological side effects. Acute renal failure related with intravenous immunoglobulin usage is observed in less than 1% of the subjects (14) . It may be manifested with different clinical pictures ranging from asymptomatic creatinine elevation to anuric renal failure. It is generally observed following use of high dose IVIG and spontaneously improves in 4-10 days. It is thought that renal failure develops as a result of sucrose which is found in IVIG preperations and can not be metabolized and which accumulates in the tubules as a result of tubular reabsorption leading to obstruction (7-9).
Actual hyponatremia which develops following administration of intravenous immunoglobulin is thought to be related with sucrose and free water load found inside the product. Sucrose causes to hyponatremia by providing fluid passage from the intravascular area into the extravascular area and free water causes to hyponatremia by creating water load mostly in individuals with tubular damage (15) .
Pseudohyponatremia develops in relation with protein and lipids found in IVIG (15 
Infectious diseases
In prophylactic treatment for viral or pathogenic infections in cases where intramuscular injection is contraindicated or hyperimmunoglobulin can not be found Transient neutropenias may be observed in relation with use of intravenous immunoglobulin. It is thought that this may be related with immunoglobulin or complement-mediated neutrophil activation and neutrophil activation or migration which develops as a result of increased adhesion molecules. On the other hand, it is also thought that anti-neutrophil antibody or cyalic acid binding immunoglobulin-like lectin-9-Siglec-9 may lead to neutropenia (19) (20) (21) .
e) Dermatological side effects: Dishydrosis (small vesicles on the hands and feet) and eczematous reactions may be observed following use of intravenous immunoglobulin. Generally, good response is obtained with topical steroids (22) .
f ) Side effects related with the lung: Dyspnea and wheezing are observed more frequently, but severe side effects including pulmonary emboly, pulmonary edema, pleuresia and transfusion related lung disease are also reported (23-25).
3) Late reactions: These are the side effects which are observed weeks-months after intravenous immunoglobulin usage.
-Passive antiviral and antibacterial antibodies which are trasferred by intravenous immunoglobulin affect the serological results and inhibit response to vaccines. Terefore, IDSA (Infectious Diseases Society of America) 2013 guideline recommends live viral vaccines to be administered 8 months after administration of low dose (400 mg/kg) IVIG and 11 months after administration of high dose (2 g/ kg) IVIG (26).
-Transmission of viruses including hepatitis B virus (HBV), Human immune deficiency virus (HIV) and hepatitis C virus (HCV) has been very rarely reported with administration of immunoglobulins (2) . No transmission of prions has been reported so far. In order to prevent these transmissions, selection of plasma donors should be made carefully, all known viral agents should be screened with polymerase chain reaction (PCR) and transaminases should be checked not to miss the window period of viral infections. Even if these procedures have been fulfilled, the donor's plasma should be kept until a plasma sample is obtained from the same donor and tested and should be used only if the tests belonging to the second sample are negative. All manufacturer institutions should additionally perform complementary purifying and virucidal procedures (especially precipitation with ethanol, fatty acid treatment, deep filtration, chromatography, solvent/detergent treatment for enveloped viruses and viral filtration for non-enveloped viruses). Even if it is considered that IVIG produced by these purifying procedures does not contain pathogens, patients who receive IVIG should be closely followed up in terms of the possibility of many unknown viruses/prions (27) .
Areas of usage
Intravenous immunoglobulin is used for replacement in immunodeficiencies and as immunomodulator in autoimmune/systemic diseases. Although the absolute indications of intravenous immunoglobulin are limited, it has been clinically shown to be beneficial in many diseases (28).
1) Replacement treatment
a) It is generally administered at a dose of 400-500 mg/ kg every 3-4 weeks for prophylaxis against recurrent infections in primary immune deficiencies (6, 29, 30) .
b) In secondary immune deficiencies (chronic lymphoid leukemia, multiple myeloma), it is used at a similar dose and frequency to decrease the risk of severe and recurrent infections which would develop in relation with decreased antibody production (31).
c) In acquired immune deficieny in the childhood: It may be used at a dose of 0.2-0.4 g/kg every 4 weeks for treatment in opportunistic infections related with hypogammaglobulinemia, recurrent bacterial infections and/or inefficient antibiotic and antiretroviral treatment in HIV positive children (29, 30) .
2) Immunomodulator
High dose IVIG acts as an antiinflammatory agent and inhibits the immune system. Due to this action, it is used in autoimmune and/or inflammatory diseases, hematologic, rheumatic and neurological diseases.
a) Immune thrombocytopenic purpura (ITP):
In hemorrhagic ITP and in patients who are being prepared for surgical intervention, IVIG can be used at a dose of 1 g/kg/day for two days or 0.4 g/kg/day for five days (6, 28, 32).
b) Kawasaki disease:
Here, it is recommneded to be used at a dose of 2 g/kg for a single day or in divided doses in five days. Administration in divided doses in five days has been shown to be more efficient in preventing coronary artery aneurism. Acetylssalicylic acid is used in addition to IVIG for treatment of this disease (28, 30, 33) .
c) Gullian-Barre Syndrome: Recovery is observed in two weeks with use of IVIG. IVIG at a dose of 1 g/kg/day or 0.5 g/kg/day for five days can be used for treatment (28, 34) .
There are also other diseases for which IVIG is used in addition to the above mentioned diseases and these are shown in Table 2 .
Conclusively, intravenous immunoglobulins which have definite and partial indications at different times and doses in almost all areas of medicine for more than 40 years and which are the main biological products are being used more frequently in our country and in the whole world with the development of plasma industry. There are no common, definite and severe side effects which limit the usage of IVIG, but studies about its benefits in many diseases for which no definite success has been obtained in treatment are being conducted. Considering the etiologies of diseases, strenghtening the host's defense against internal and external agents is one of the most important theraputic aims of medicine. IVIG which has an important role to achive this will be continued to be used with further development in terms of safety and quality and with wider production.
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